On this page
Quick Reference
Overview and Recommendations
Background
- •Recurrence after curative for is common, occurring in 37-40% of patients. The pattern, local (anastomotic/tumor bed), regional (mediastinal, supraclavicular, celiac nodes), or distant (liver, lung, brain, bone), directs subsequent management. Distant metastases account for 49-55% of first recurrences, with the remainder being locoregional or mixed.
- •The highest risk period is the first 2 years after surgery, with a recurrence rate of 27 per 100 person-years in year 1, declining to 4 per 100 person-years by year 6. Patients who received neoadjuvant therapy have a higher early recurrence rate (35 vs 14 per 100 person-years in the first 2 years).
- •Site of recurrence carries prognostic significance. Lung-only recurrence has a more indolent course (median overall survival 2.41 years), whereas liver-only (8.3 months) and brain-only (0.95 years) recurrences are more aggressive. Multiple distant sites at first recurrence portend the worst survival (median 7.4 months).
- •The systemic immune-inflammation index (SII), calculated as platelet count × neutrophil count / lymphocyte count, is an independent prognostic factor at recurrence. Using a cutoff of 500, 1-year overall survival is 84.9% in the low-risk group vs 28.8% in the high-risk group (HR 2.833).
- •Pathologic complete response (pCR) to neoadjuvant therapy is associated with longer survival after brain recurrence (median 1.56 vs 0.66 years). In patients with pCR, isolated brain metastasis may represent true oligorecurrence rather than the first sign of widespread disease.
Evaluation
- •Suspect recurrence in any patient with new or worsening dysphagia, odynophagia, weight loss, pain, cough, or neurologic deficits. Recurrence may also be detected on routine surveillance imaging in asymptomatic patients.
- •Obtain a detailed history including symptoms, performance status, and prior treatment details (surgery, neoadjuvant therapy, radiation dose).
- •Perform a focused physical examination: assess for supraclavicular lymphadenopathy, abdominal masses, and neurologic deficits.
- •Order CT chest and abdomen with intravenous contrast as the initial imaging modality. CT detects 45% of asymptomatic recurrences.
- •If CT is equivocal for distant recurrence, consider FDG-PET/CT to identify metabolically active lesions and guide biopsy.
- •In patients with pathologic complete response after neoadjuvant therapy, obtain brain MRI if new neurologic symptoms arise or if isolated brain metastasis is suspected. Isolated brain recurrence occurs in 2% of patients.
- •Surveillance endoscopy has limited value, detecting only 1% of asymptomatic local recurrences. Reserve for symptomatic anastomotic recurrence or when mucosal lesion is suspected.
- •Obtain tissue biopsy of suspicious lesions whenever feasible to confirm recurrence and test for actionable molecular alterations (e.g., HER2, MSI, PD-L1).
- •Calculate the systemic immune-inflammation index (SII) from routine complete blood count: platelet count (×10³/mm³) × neutrophil count (cells/mm³) / lymphocyte count (cells/mm³). A cutoff of 500 stratifies prognosis.
- •Consider the REEC model (alcohol consumption, TNM classification, number of lymph node station metastases, number of lymph node metastases) for predicting recurrence risk, though its clinical utility is limited by modest AUC (0.65-0.68).
- •Assess Charlson comorbidity index and performance status to guide treatment intensity and palliative care referral.
Management
- •For isolated local-regional recurrence (anastomotic, tumor bed, or regional nodes), pursue definitive therapy with curative intent in appropriate candidates. Options include salvage surgery, definitive chemoradiation, or endoscopic resection.
- •Salvage surgery for solitary mediastinal lymph node recurrence can achieve R0 resection with median overall survival of 43 months. Resection of isolated nodal recurrence combined with systemic therapy improves survival over systemic therapy alone (P < 0.001).
- •Definitive chemoradiation for local-regional recurrence is effective and its efficacy is not diminished by prior neoadjuvant chemotherapy, even when the same agents are used.
- •For anastomotic recurrence in the gastric tube, endoscopic resection is feasible but carries a higher bleeding rate (17.6%) and requires lifelong surveillance for metachronous lesions.
- •For distant metastatic disease, initiate first-line systemic therapy with a platinum/fluoropyrimidine doublet: 800 mg/m² continuous infusion days 1-5 plus 80 mg/m² day 1, every 3-4 weeks.
- •Add an immune checkpoint inhibitor ( or ) to first-line chemotherapy based on PD-L1 expression and tumor type. In squamous cell carcinoma, nivolumab plus chemotherapy is approved; in adenocarcinoma, pembrolizumab plus chemotherapy is an option.
- •Second-line options include taxanes ( 175 mg/m² every 3 weeks or 75 mg/m² every 3 weeks) or checkpoint inhibitor monotherapy if not used in first line.
- •For patients with oligometastatic disease (single site, long disease-free interval ≥12 months, good performance status), consider metastasis-directed therapy: surgical resection, stereotactic body radiotherapy (SBRT), or definitive chemoradiation.
- •Lung oligometastases have the most favorable prognosis (median OS 2.41 years) and are optimal targets for SBRT or metastatectomy. Liver and brain oligometastases require rapid systemic therapy, though local therapy may provide palliative benefit.
- •For isolated brain metastasis, especially in patients with pCR after neoadjuvant therapy, consider surgical resection or stereotactic radiosurgery. Median survival after brain recurrence is 0.95 years overall, but 1.56 years in pCR patients.
- •Avoid non-dihydropyridine calcium channel blockers (diltiazem, verapamil) in patients with heart failure or reduced LVEF, though this is not specific to esophageal cancer.
- •Monitor for treatment-related toxicities: cisplatin-induced nephrotoxicity (prehydrate, monitor creatinine), 5-FU cardiotoxicity (consider capecitabine if history of CAD), and immune-related adverse events (colitis, pneumonitis, hepatitis).
- •Refer to palliative care early for symptom management (dysphagia, pain, weight loss) and advance care planning. Consider esophageal stenting for malignant dysphagia.
- •Discharge criteria for inpatient management: stable vital signs, adequate oral intake or enteral nutrition, pain controlled, and follow-up arranged with medical oncology and palliative care.
- •Surveillance after treatment of recurrence: CT chest/abdomen every 3-6 months for the first 2 years, then every 6-12 months. Imaging yield diminishes after year 6.
Board Review — High Yield
- •Recurrence rate, 37-40% after curative esophagectomy; highest in first 2 years (27 per 100 person-years).
- •Site-specific prognosis, Lung-only recurrence: median OS 2.41 years; liver-only: 8.3 months; brain-only: 0.95 years.
- •Systemic Immune-Inflammation Index (SII), Platelet × neutrophil / lymphocyte; cutoff 500: 1-year OS 84.9% vs 28.8%.
- •Oligometastatic disease, Single site, long DFI, good PS; treat with definitive local therapy (surgery/SBRT) for potential long-term control.
- •First-line systemic therapy, Platinum/fluoropyrimidine doublet + immune checkpoint inhibitor (nivolumab or pembrolizumab).
- •Salvage surgery, For isolated nodal recurrence, median OS 43 months; R0 resection achievable.
- •Brain metastasis, Occurs in 2%; pCR patients have better survival (1.56 vs 0.66 years); consider resection/SRS.
- •REEC model, Predicts recurrence with sensitivity, specificity (AUC 0.65-0.68).
- •Dietary factors, Higher folate intake reduces ESCC mortality (HR 0.41); alcohol increases all-cause mortality (HR 1.29).
- •Surveillance imaging, CT detects 45% of asymptomatic recurrences; associated with longer OS after recurrence (23 vs 16 months).
Deep Dive — Evidence Details
Patterns of Recurrence
- ▸Recurrence is common (37-40%), with highest risk in first 2 years post-surgery.
- ▸Lung oligometastases have significantly better prognosis than liver or brain metastases.
After curative , recurrence occurs in 37-40% of patients. Distant/systemic recurrence is most common (27-37%), followed by regional (7.7-28%) and local (2.2-14.4%) [4]B3b[15]D5[5]C4. The highest risk period is the first 2 years, with rates of 27 per 100 person-years in year 1 declining to 4 by year 6 [5]C4. Neoadjuvant therapy increases early recurrence (35 vs 14 per 100 person-years) [5]C4. Site-specific prognosis varies: lung oligometastases have median overall survival (OS) of 2.41 years vs 0.95 years for brain or liver [12]D5. Liver-only recurrence appears earlier (median 9.0 months) and has worse postrecurrence survival (8.3 months) [15]D5. Predictors of isolated nodal recurrence include neoadjuvant radiation dose <45 Gy (HR 3.5), node-positive disease (HR 1.9), and lymphovascular invasion (HR 1.6) [4]B3b. The systemic immune-inflammation index (SII) at recurrence diagnosis stratifies survival: cutoff 500 gives 1-year OS 84.9% vs 28.8% (HR 2.833) [10]C4.
Pearl: Site of recurrence carries prognostic significance: lung oligometastases have better survival (median 2.41 years) than liver or brain (0.95 years each).
| Study | N | Recurrence rate | Distant (%) | Regional (%) | Local (%) | Key finding |
|---|---|---|---|---|---|---|
| Boerner et al. [4]B3b | 1626 | 37% | 27% | 7.7% | 2.2% | Dose <45 Gy predicts nodal recurrence |
| Lou et al. [5]C4 | 1147 | 38% | 55% | 28% (combined) | , | Half detected by symptoms |
| ENSURE [15]D5 | 3299 | 40% | 71% (distant) | , | 14.4% | Liver-only worst prognosis |
| Nobel et al. [1]B2b | 1760 | 39% | 2% isolated brain | , | , | All iBMEC had neoadjuvant therapy |
Workup of Suspected Recurrence
- ▸SII at recurrence diagnosis is a powerful prognostic tool (cutoff 500).
- ▸Brain MRI is indicated for pCR patients with new neurological symptoms.
High index of suspicion is needed as up to 39% recur after [3]B3b. Detection rates are similar between surveillance imaging (SI) and history/physical (HPE) (40.6% vs 37.9%), but SI is associated with longer median OS (23 vs 16 months) [3]B3b. Chest/abdominal CT detects 45% of asymptomatic recurrences [5]C4. FDG-PET/CT is used when CT is equivocal for distant disease. Brain MRI should be considered in patients with pathologic complete response (pCR) after neoadjuvant therapy, as isolated brain metastasis occurs in 2% [1]B2b. Surveillance endoscopy has limited value (1% detection) [5]C4. The systemic immune-inflammation index (SII) = platelet count × neutrophil count / lymphocyte count; cutoff 500 stratifies prognosis (1-year OS 84.9% vs 28.8%, HR 2.833) [10]C4. The REEC model (alcohol, TNM, lymph node stations) predicts recurrence with sensitivity 76.68% and specificity 51.18% at cutoff 1.095 [8]B3b. Tissue biopsy confirms recurrence and allows molecular testing.
Pearl: In patients with pathologic complete response after neoadjuvant therapy, a new brain lesion should prompt brain MRI and consideration of resection, as these patients may have isolated brain metastasis with a better prognosis (median OS 1.56 vs 0.66 years, P =.019) [1]B2b.
Local-Regional Recurrence
- ▸Isolated local-regional recurrence may be amenable to curative salvage therapy.
- ▸SII at recurrence predicts survival and guides treatment intensity.
Local-regional recurrence occurs in 25-35% of patients who recur after [4]B3b[15]D5. Isolated local recurrence presents later (median 17.8 months) and has better postrecurrence survival (15.9 months) than liver-only (9.0 months, 8.3 months) [15]D5. Risk factors for regional nodal recurrence include neoadjuvant radiation dose <45 Gy (HR 3.5), node-positive disease (HR 1.9), and lymphovascular invasion (HR 1.6) [4]B3b. Detection: 50% by symptoms, 45% by routine CT, only 1% by surveillance endoscopy [5]C4. Treatment options: salvage surgery (R0 resection in 5/6 patients with solitary mediastinal node recurrence, median OS 43 months) [18]D5; definitive chemoradiation (efficacy not diminished by prior neoadjuvant chemotherapy) [9]B3b; endoscopic resection for anastomotic recurrence (higher bleeding rate 17.6%) [13]D5. Prognosis: local-only recurrence median postrecurrence survival 15.9 months [15]D5. SII cutoff 500 stratifies 1-year OS (84.9% vs 28.8%) [10]C4.
Pearl: For patients with isolated local-regional recurrence, especially single-station nodal disease, aggressive definitive therapy with surgery or chemoradiation can achieve prolonged survival (median >2 years) and should be pursued in appropriate candidates.
| Risk Factor | Hazard Ratio (95% CI) | P Value |
|---|---|---|
| Neoadjuvant chemoradiation dose <45 Gy | 3.5 (1.7-7.3) | 0.001 |
| Pathologic node-positive disease | 1.9 (1.3-3.0) | 0.003 |
| Lymphovascular invasion | 1.6 (1.0-2.5) | 0.049 |
| Increasing age (per year) | 0.97 (0.96-0.99) | 0.001 |
| Increasing number of excised lymph nodes | 0.98 (0.95-1.00) | 0.021 |
Distant Metastatic Disease
- ▸Liver-only recurrence has worst prognosis; lung-only has best among distant sites.
- ▸SII ≥500 identifies patients with very poor prognosis (1-year OS 28.8%).
Distant metastases account for 49-55% of first recurrences after curative-intent therapy [5]C4[22]B3b. Median time to recurrence is 9.9 months (IQR 5.4-18.8) [22]B3b. Site-specific outcomes: liver-only recurrence appears earliest (median 9.0 months) and has worst postrecurrence survival (8.3 months); lung-only appears later (15.2 months) with better survival (10.4 months); multiple distant sites have poorest survival (7.4 months) [15]D5. Isolated brain metastasis occurs in 2% (median OS 0.95 years; pCR patients fare better: 1.56 vs 0.66 years) [1]B2b. The SII (cutoff 500) is an independent prognostic factor: 1-year OS 28.8% (high) vs 84.9% (low) [10]C4. First-line systemic therapy: platinum/fluoropyrimidine doublet (e.g., 800 mg/m² days 1-5 + 80 mg/m² day 1) with or without immune checkpoint inhibitor ( or ) [10]C4. Second-line: taxanes or checkpoint inhibitor monotherapy [10]C4. Surveillance CT identifies 45% of recurrences; detection by imaging is associated with longer OS (23 vs 16 months) [3]B3b.
Pearl: The SII, calculated from routine blood counts, stratifies prognosis and treatment initiation rates in patients with distant metastatic recurrence; a cutoff of 500 identifies a high-risk group with 1-year survival of only 28.8% [10]C4.
Oligometastatic Disease
- ▸Lung oligometastases have the best prognosis among distant sites (median OS 2.41 years).
- ▸Selected patients with oligometastatic disease may achieve long-term survival with aggressive local therapy.
Oligometastasis represents an intermediate state between localized and systemic disease. Site-specific prognosis varies: lung oligometastases have median OS 2.41 years (95% CI 1.58-3.31), brain 0.95 years (HR 4.48 vs lung), liver 0.95 years (HR 2.94) [12]D5. 80% of liver, 51% of brain, and 44% of lung recurrences occur within 12 months [12]D5. Patient selection for definitive local therapy: single site of recurrence, disease-free interval ≥12 months, good performance status, no widespread disease on restaging. In a series of 27 patients with isolated recurrence treated with curative intent, median OS from recurrence was 25.2 months (3-year estimated survival 33%) [21]C4. Treatment modalities: surgical resection (e.g., for solitary metastases can yield long-term DFS; reported 22 and 92 months) [11]C4; resection of solitary mediastinal lymph node recurrence achieved R0 in 5/6 patients with median OS 43 months [18]D5; definitive chemoradiation for non-surgical candidates [21]C4; isolated brain metastasis in pCR patients has median OS 1.56 years vs 0.66 years (P=0.019) [1]B2b.
Pearl: For patients with isolated lung oligometastasis after esophagectomy, median survival exceeds 2 years with aggressive local therapy, supporting a paradigm shift from palliative-only care to potentially curative intervention in this selected subgroup.
Prognosis of Recurrent Disease
- ▸SII and site of recurrence are the strongest prognostic factors.
- ▸Modifiable factors (folate intake, alcohol) affect survival in ESCC.
Prognosis after recurrence is poor: median OS 11.2 months (95% CI 5.2-17.2) [10]C4 and 0.95 years [1]B2b. Recurrence risk is highest in first 2 years (27 per 100 person-years year 1, declining to 4 by year 6) [5]C4. Neoadjuvant therapy increases early recurrence rate (35 vs 14 per 100 person-years) [5]C4. Key prognostic factors: SII (cutoff 500: 1-year OS 84.9% vs 28.8%, HR 2.833) [10]C4; REEC index (sensitivity 76.68%, specificity 51.18% at cutoff 1.095) [8]B3b; site of recurrence (local-only 15.9 months, lung-only 10.4 months, liver-only 8.3 months, multiple 7.4 months) [15]D5; pCR status (brain recurrence: 1.56 vs 0.66 years) [1]B2b; comorbidity (CCI ≤2: 5-year OS 88.2% vs 60.2%) [14]D5; dietary folate in ESCC (HR 0.41 for mortality) [2]B2a; alcohol consumption (HR 1.29 for all-cause mortality) [2]B2a.
Pearl: The SII at the time of recurrence diagnosis is a simple, widely available tool that stratifies patients into widely divergent prognostic groups, a cutoff of 500 identifies those with a 1-year survival of 28.8% vs 84.9%, and can guide decisions about treatment intensity and palliative care referral [10]C4.
References
- [1]
Nobel TB, Dave N, Eljalby M et al.. “Incidence and Risk Factors for Isolated Esophageal Cancer Recurrence to the Brain.” The Annals of thoracic surgery (2019). PMID: 31614136 ↗
L2PROSPECTIVE_COHORTCited in: Patterns of Recurrence, Workup of Suspected Recurrence, Local-Regional Recurrence, Distant Metastatic Disease, Oligometastatic Disease, Prognosis of Recurrent Disease - [2]
Sun LP, Yan LB, Liu ZZ et al.. “Dietary factors and risk of mortality among patients with esophageal cancer: a systematic review.” BMC cancer (2020). PMID: 32252671 ↗
L2SR_COHORTCited in: Patterns of Recurrence, Local-Regional Recurrence, Distant Metastatic Disease, Oligometastatic Disease, Prognosis of Recurrent Disease - [3]
Chang C, Linden PA, Jiang B et al.. “Monitoring for Recurrence After Esophagectomy.” The Annals of thoracic surgery (2021). PMID: 34793765 ↗
L3COHORTCited in: Patterns of Recurrence, Workup of Suspected Recurrence, Local-Regional Recurrence, Distant Metastatic Disease, Oligometastatic Disease - [4]
Boerner T, Carr RA, Hsu M et al.. “Incidence and management of esophageal cancer recurrence to regional lymph nodes after curative esophagectomy.” International journal of cancer (2023). PMID: 36573352 ↗
L3RETROSPECTIVE_COHORTCited in: Patterns of Recurrence, Local-Regional Recurrence, Distant Metastatic Disease, Oligometastatic Disease - [5]
Lou F, Sima CS, Adusumilli PS et al.. “Esophageal cancer recurrence patterns and implications for surveillance.” Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2013). PMID: 24389438 ↗
L4RETROSPECTIVE_COHORTCited in: Patterns of Recurrence, Workup of Suspected Recurrence, Local-Regional Recurrence, Distant Metastatic Disease, Oligometastatic Disease, Prognosis of Recurrent Disease - [6]
Harris TR, Elkamel AAA, Wang K et al.. “Predictors of overall survival in esophageal cancer patients with pathologic complete response after neoadjuvant therapy and surgery.” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2025). PMID: 40479618 ↗
L3COHORTCited in: Patterns of Recurrence, Local-Regional Recurrence, Distant Metastatic Disease, Oligometastatic Disease, Prognosis of Recurrent Disease - [7]
Xu P, Liu Y, Wu S et al.. “Meta analysis of the second course of radiotherapy for recurrent esophageal cancer1.” Journal of X-ray science and technology (2024). PMID: 37424494 ↗
L2SR_COHORTCited in: Patterns of Recurrence - [8]
Wang W, Chen Y, Zhang X et al.. “A Model Shows Utility in Predicting Postoperative Recurrence and Distant Metastasis in Curatively Resected Esophageal Squamous Cell Cancer.” Cancer control : journal of the Moffitt Cancer Center (2019). PMID: 31146546 ↗
L3COHORTCited in: Patterns of Recurrence, Workup of Suspected Recurrence, Local-Regional Recurrence, Distant Metastatic Disease, Oligometastatic Disease, Prognosis of Recurrent Disease - [9]
Taniyama Y, Sakurai T, Hikage M et al.. “How does presurgical chemotherapy influence the efficiency of treatment for esophageal cancer recurrence after curative esophagectomy?” Thoracic cancer (2019). PMID: 30756477 ↗
L3COHORTCited in: Patterns of Recurrence, Local-Regional Recurrence, Distant Metastatic Disease, Oligometastatic Disease, Prognosis of Recurrent Disease - [10]
Aoyama T, Maezawa Y, Hashimoto I et al.. “The Systemic Immune-inflammation Index (SII) Is an Independent Prognostic Factor for Patients With Recurrent Esophageal Cancer After Esophagectomy.” In vivo (Athens, Greece) (2025). PMID: 40578991 ↗
L4COHORTCited in: Patterns of Recurrence, Workup of Suspected Recurrence, Local-Regional Recurrence, Distant Metastatic Disease, Oligometastatic Disease, Prognosis of Recurrent Disease - [11]
Huddy JR, Thomas RL, Worthington TR et al.. “Liver metastases from esophageal carcinoma: is there a role for surgical resection?” Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (2014). PMID: 24898890 ↗
L4CASE_SERIESCited in: Patterns of Recurrence, Local-Regional Recurrence, Distant Metastatic Disease, Oligometastatic Disease, Prognosis of Recurrent Disease - [12]
Nobel TB, Sihag S, Xing X et al.. “Oligometastases After Curative Esophagectomy Are Not One Size Fits All.” The Annals of thoracic surgery (2021). PMID: 33689743 ↗
L5OTHERCited in: Patterns of Recurrence, Workup of Suspected Recurrence, Local-Regional Recurrence, Distant Metastatic Disease, Oligometastatic Disease, Prognosis of Recurrent Disease - [13]
Inokuchi Y, Watanabe M, Hayashi K et al.. “Feasibility, efficacy, and cautionary note of endoscopic resection for gastric tube cancer after esophagectomy.” Surgical endoscopy (2022). PMID: 35604483 ↗
L5OTHERCited in: Patterns of Recurrence, Local-Regional Recurrence, Distant Metastatic Disease, Oligometastatic Disease, Prognosis of Recurrent Disease - [14]
Kim GH, Na HK, Ahn JY et al.. “Long-term Outcomes and Factors Affecting the Survival of Patients with Mucosal Esophageal Squamous Cell Carcinoma.” Gut and liver (2021). PMID: 33462160 ↗
L5OTHERCited in: Patterns of Recurrence, Local-Regional Recurrence, Distant Metastatic Disease, Oligometastatic Disease, Prognosis of Recurrent Disease - [15]
Goense L, Elliott JA, Markar SR et al.. “Patterns, Timing, and Survival of Recurrence After Surgery for Esophageal and Junctional Adenocarcinoma in the European Multicentre ENSURE Study.” Annals of surgical oncology (2026). PMID: 41942778 ↗
L5OTHERCited in: Patterns of Recurrence, Local-Regional Recurrence, Distant Metastatic Disease, Oligometastatic Disease, Prognosis of Recurrent Disease - [16]
Badreddine RJ, Prasad GA, Lewis JT et al.. “Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2009). PMID: 19948247 ↗
L5OTHERCited in: Patterns of Recurrence, Local-Regional Recurrence, Distant Metastatic Disease, Oligometastatic Disease - [17]
Yoshikawa R, Fujiwara Y, Koishi K et al.. “Cyclooxygenase-2 expression after preoperative chemoradiotherapy correlates with more frequent esophageal cancer recurrence.” World journal of gastroenterology (2007). PMID: 17511025 ↗
L5OTHERCited in: Patterns of Recurrence, Workup of Suspected Recurrence, Local-Regional Recurrence, Distant Metastatic Disease, Oligometastatic Disease, Prognosis of Recurrent Disease - [18]
Motoyama S, Sato Y, Wakita A et al.. “Approaches to resection of recurrent solitary mediastinal lymph nodes after esophagectomy.” Esophagus : official journal of the Japan Esophageal Society (2020). PMID: 33216243 ↗
L5OTHERCited in: Patterns of Recurrence, Local-Regional Recurrence, Distant Metastatic Disease, Oligometastatic Disease - [19]
Nakajima Y, Ohta S, Okada T et al.. “Osteoplastic bone metastasis in esophageal squamous cell cancer: report of a case.” Surgery today (2011). PMID: 22089695 ↗
L4CASE_SERIESCited in: Patterns of Recurrence - [20]
Kitagawa H, Namikawa T, Iwabu J et al.. “Gastric Tube Reconstruction with Superdrainage Using Indocyanine Green Fluorescence During Esophagectomy.” In vivo (Athens, Greece) (2017). PMID: 28882975 ↗
L4CASE_SERIESCited in: Patterns of Recurrence - [21]
Port JL, Nasar A, Lee PC et al.. “Definitive therapy for isolated esophageal metastases prolongs survival.” The Annals of thoracic surgery (2012). PMID: 22621874 ↗
L4COHORTCited in: Local-Regional Recurrence, Distant Metastatic Disease, Oligometastatic Disease - [22]
Abdallah FA, Ortiz BA, Vierkant RA et al.. “Esophageal cancer recurrence after multimodality therapy: analysis of patterns and implications on long-term survival.” Journal of thoracic disease (2026). PMID: 42306686 ↗
L3COHORTCited in: Local-Regional Recurrence, Distant Metastatic Disease, Oligometastatic Disease - [23]
Han J, Hayashi S, Takahashi RU et al.. “Leukocyte Telomeric G-Tail Length Shortening Is Associated with Esophageal Cancer Recurrence.” Journal of clinical medicine (2022). PMID: 36556001 ↗
L3CASE_CONTROLCited in: Local-Regional Recurrence, Distant Metastatic Disease, Oligometastatic Disease
Backlinks
- ← Esophageal Cancer Systemic Therapy (Detailed)
- ← Esophageal Cancer Systemic Therapy
- ← Esophageal Cancer Surveillance and Follow-up
- ← Esophageal Cancer Surgical Management (Detailed)
- ← Esophageal Cancer Radiation Management (Detailed)
- ← Esophageal Cancer Surgical Management
- ← Esophageal Cancer (Detailed)
- ← Esophageal Cancer Surveillance and Follow-up (Detailed)
- ← Esophageal Cancer Palliative Care (Detailed)
- ← Esophageal Cancer Palliative Care